Latest Ratios: P/E Ratio -4.1x · EV/EBITDA N/A · ROE -10.7%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $8M | $15M | $11M | $20M | $53M | $78M | $460M | $424M | — |
| Enterprise Value | $5M | $8M | $18M | $13M | $25M | $45M | $78M | $461M | $422M | — |
| P/E Ratio → | -4.05 | — | — | — | — | — | 12.35 | — | — | — |
| P/S Ratio | — | — | — | 25.68 | 15.15 | 34.08 | 85.44 | 859.19 | 1104.90 | — |
| P/B Ratio | 0.41 | 0.57 | 1.30 | 0.72 | 2.51 | 3.00 | 2.04 | 30.96 | 12.94 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 29.11 | 18.98 | 28.94 | 85.25 | 861.59 | 1100.44 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 15.05 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 2.4% | 6.2% | 5.3% | -11.4% | -48.4% | 17.1% | — |
| Operating Margin | — | — | — | -2457.5% | -1351.0% | -1245.6% | -2182.6% | -3400.4% | -2693.4% | — |
| Net Profit Margin | — | — | — | -654.9% | -756.2% | -1624.4% | 775.3% | -3491.8% | -3868.0% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -10.7% | -10.7% | -31.4% | -24.3% | -77.3% | -90.0% | 26.7% | -78.5% | -47.1% | -8.4% |
| ROA | -7.8% | -7.8% | -23.2% | -13.6% | -45.8% | -75.7% | 20.7% | -54.1% | -38.7% | -8.1% |
| ROIC | -9.7% | -9.7% | -18.3% | -53.6% | -117.3% | -60.6% | -55.1% | -57.9% | -34.1% | -29.5% |
| ROCE | -14.0% | -14.0% | -25.0% | -78.8% | -135.2% | -66.4% | -64.5% | -67.2% | -32.7% | -18.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.28 | 0.23 | 0.88 | 0.01 | 0.09 | 0.44 | 0.31 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | 0.21 | 0.10 | 0.63 | -0.45 | -0.00 | 0.09 | -0.05 | -0.52 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -18.99 | -18.99 | -27.30 | -87.51 | — | -288.68 | 21.20 | -4.44 | -2.39 | — |
Net cash position: cash ($3M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.78 | 0.78 | 0.22 | 1.18 | 0.57 | 2.90 | 8.70 | 3.00 | 2.36 | 15.24 |
| Quick Ratio | 0.78 | 0.78 | 0.22 | 1.18 | 0.56 | 2.89 | 8.69 | 2.99 | 2.35 | 14.09 |
| Cash Ratio | 0.75 | 0.75 | 0.20 | 0.96 | 0.16 | 1.91 | 8.24 | 2.34 | 1.07 | 13.69 |
| Asset Turnover | — | — | — | 0.02 | 0.06 | 0.07 | 0.02 | 0.02 | 0.01 | — |
| Inventory Turnover | — | — | — | — | 43.86 | 40.81 | 25.94 | 23.24 | 10.38 | 0.04 |
| Days Sales Outstanding | — | — | — | 60.03 | 332.53 | 842.90 | 136.57 | 332.55 | 943.17 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 1.0% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | 10.7% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 8.1% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $7M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M |
Critical liquidity depletion
Based on current market data, Aptorum trades at a price-to-book ratio of 0.41, which, according to recent financial filings, suggests the market is pricing the company significantly below its net asset value due to extreme skepticism regarding the commercial viability of its multi-asset clinical pipeline.
The negative P/E ratio of -4.07 confirms the absence of earnings, rendering traditional valuation multiples largely irrelevant for assessing intrinsic value. Investors appear to be treating the equity as a deep out-of-the-money option, where the primary risk is not just clinical failure, but the high probability of further dilutive financing to sustain operations.
As reported in historical financial statements, the company's ROIC has consistently trended in negative territory, reaching -5.4% in 2024Q4, which indicates that the capital deployed into the drug repurposing platform has failed to generate any meaningful economic return for shareholders over the long term.
The persistent decay in return on invested capital suggests that the company's R&D expenditures are not currently creating value, but rather consuming the equity base. Without a clear path to commercialization, these returns are unlikely to improve, as the cost of capital continues to outpace the company's ability to de-risk its therapeutic assets.
Based on the most recent quarterly data, Aptorum's current ratio has plummeted to 0.22, a stark deterioration from the 8.70 ratio observed in 2020Q4, which indicates that the company's liquid assets are now severely insufficient to cover its near-term liabilities and ongoing operational burn requirements.
This liquidity profile suggests a high risk of insolvency if the company cannot secure immediate external funding. The rapid decline in the quick ratio mirrors the current ratio, confirming that the company lacks the inventory or liquid assets necessary to bridge the gap between its current cash position and future clinical milestones.
While the company's debt-to-equity ratio of 0.28 appears modest, as indicated by recent financial statements, this figure likely reflects a lack of access to traditional credit markets rather than a position of financial strength, given the company's pre-revenue status and limited cash reserves.
Analysts often misinterpret low leverage in biotech as a sign of balance sheet health, but in this case, it obscures the reality that the company is effectively shut out of debt markets. A more appropriate metric for this business model would be the cash burn rate relative to total liquidity, which provides a clearer picture of the remaining operational runway.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying APM stock.
Aptorum Group Limited's current P/E ratio is -4.1x. The historical average is 12.3x.
Aptorum Group Limited's return on equity (ROE) is -10.7%. The historical average is -37.9%.
Based on historical data, Aptorum Group Limited is trading at a P/E of -4.1x. Compare with industry peers and growth rates for a complete picture.